Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from ChinaBio Today

03:08 EST 22nd January 2018 | BioPortfolio

Here are the most relevant search results for "ChinaBio Today" found in our extensive news archives from over 250 global news sources.

More Information about ChinaBio Today on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about ChinaBio Today for you to read. Along with our medical data and news we also list ChinaBio Today Clinical Trials, which are updated daily. BioPortfolio also has a large database of ChinaBio Today Companies for you to search.

Showing News Articles 1–25 of 346 from ChinaBio Today

Sunday 21st January 2018

Week in Review: Sinocare Eyes $4 Billion Deal for J&J Diabetes Device Business

Deals and Fundings Sinocare of Changsha may bid as much as $4 billion to acquire Johnson & Johnson's diabetes medical device subsidiaries; China’s Ping An Healthcare Management closed a nearly $1 billion pre-IPO round for its healthcare platform and plans a Hong Kong IPO later in the year; BeiGene, a Beijing novel cancer company, raised $750 million in a secondary offering, giving the ...

Saturday 20th January 2018

China's Adlai Nortye Acquires Immuno-oncology Candidate from Eisai

Adlai Nortye Biopharma of Hangzhou acquired global rights to a novel immuno-oncology oral EP4 antagonist developed by Japan's Eisai Co. Eisai has reported positive results from a Phase I test of the drug in Japan, where it will retain rights. Adlai Nortye will have exclusive worldwide research, development, manufacturing and commercialization rights to E7046, excluding Japan and some

Ascletis Plans $100 Million C Round; Then Hong Kong IPO

Ascletis, a Hangzhou company developing a oral interferon-free combination treatment for hepatitis C, is planning a $100 million C funding. The company will use the money to fund clinical trials and develop a marketing operation. Previously, Ascletis raised $155 million in two rounds of venture capital, plus another $100 million in startup investment. After the C Round, Ascletis is considering an ...

BeiGene Completes $750 Million Secondary Offering

BeiGene, a Beijing innovative cancer biotech, raised a spectacular $750 million in a secondary offering of its shares. The price of the shares ended the session 13% higher after the funding was announced, closing the day at $115.56. BeiGene now has a market capitalization of $4.8 billion -- before the new shares are issued. In 2016, BeiGene staged a $158 million IPO on the Nasdaq exchange, pricing...

Friday 19th January 2018

3SBio to Market Japanese Pruritis Treatment in China

3SBio of Shenyang in-licensed China rights to a pruritis (itching) treatment developed by Japan's Toray Industries. TRK-820 is a highly selective opioid receptor agonist that is intended to treat the itching that accompanies chronic liver disease and peritoneal dialysis. 3SBio will commercialize the oral disintegration formulation of the drug to facilitate dosing in patients who have difficulty sw...

Ping An Raises $1 Billion for Healthcare Management Unit

China’s Ping An Insurance Group raised nearly $1 billion in a pre-IPO round for Ping An Healthcare Management, an open platform for healthcare services such as medical treatment, social health insurance (SHI) and drug distribution. The funding values the business at $8.8 billion. Ping An Healthcare Management plans a Hong Kong IPO later in 2018. It will follow an IPO, also in Hong Kong, for ...

Thursday 18th January 2018

Eddingpharm Starts China Trial of Amarin's Hypertriglyceridemia Treatment

Amarin reported that Eddingpharm, its China partner, has started a China registrational trial of Vascepa® (icosapent ethyl), a treatment for hypertriglyceridemia. Three years ago, Eddingpharma in-licensed greater China rights to the drug in a deal worth up to $169 million. Vascepa is a very pure, omega-3 fatty acid product available by prescription. In its US trial, Vascepa lowered trigly...

Sinocare Mulls $4 Billion Bid for J&J's Diabetes Device Companies

Sinocare, a diabetes company based in Changsha, may bid as much as $4 billion to acquire Johnson & Johnson's diabetes medical device subsidiaries. With falling revenues, some of J&J's diabetes-focused companies are exiting from the US market because they can no longer compete and revenues are falling. Sinocare is backed by China Jianyin Investment (JIC), a unit of sovereign wealth fund Chi...

Wednesday 17th January 2018

CR Pharma Negotiating for China Rights to Two Xbrane Candidates

CR Pharma, China's second-largest drugmaker, is negotiating with Sweden's Xbrane Biopharma for China rights to two Xbrane candidates. One of the drugs is Spherotide, a generic testosterone suppressor with an extended release delivery used to treat prostate cancer. The other is Xlucane, a biosimilar to Roche's Lucentis, a treatment for wet age-related macular degeneration. According to Xbrane, it h...

Tuesday 16th January 2018

BeiGene Acquires Asia Rights to Mirati Cancer Treatment in $133 Million Deal

BeiGene, a Beijing cancer company, in-licensed Asian rights to a clinical-stage lung cancer therapy from Mirati Therapeutics of San Diego. Sitravatinib is a spectrum-selective kinase inhibitor that has shown clinical efficacy in a Phase II trial in combination with a PD-1 checkpoint inhibitor. BeiGene, which will test sitravatinib in conjunction with its own PD-1 candidate, will pay $10 million up...

Suzhou's Innovent Plans Capital Raise Followed by $200 Million IPO

Innovent Biologics of Suzhou is planning a pre-IPO round and then an IPO for $200 million in late 2018. The venue will be either a US or Hong Kong exchange, according to Bloomberg. Innovent is developing an ambitious portfolio of biosimilar and novel biotech cancer drugs.  One year ago, the company completed a $260 million D round. In 2015, Innovent struck an over-$1 billion deal with Lilly, ...

UK's Vaccitech Raises $27 Million, Co-Led by Sequoia China

Vaccitech, an Oxford University spinout that is developing a universal flu vaccine along with other vaccine products, closed a $27 million Series A financing. The round was co-led by GV (formerly Google Ventures), Sequoia China, and existing backer Oxford Sciences Innovation. A clinical stage company, Vaccitech is developing six products that induce cellular immune responses using non-replicating ...

Suzhou Zelgen Biosciences Completes $62 Million B Round

Suzhou Zelgen Biosciences completed a $62 million series B financing to support its portfolio of small molecule and biologic drug candidates. Established in 2009, Zelgen is focused on cancer, hematology and auto-immune products. With the new capital, the company will advance its portfolio and prepare for commercialization of its lead product, a Phase III candidate that targets various forms of lat...

Saturday 13th January 2018

Week in Review: Hua Medicine to Raise $200 Million Through Fundings and IPO for Oral Diabetes Drug

Deals and Financings Hua Medicine will raise $200 million in fundings and an IPO to complete clinical development of its novel oral diabetes 2 treatment and commercialize the drug;  Shanghai Fosun Pharma announced a $50 million US joint venture, which consists of two Fosun companies: Fosun Pharma USA and Fosun International;  Suzhou Kintor Pharma raised $44 million in a funding to under...

Friday 12th January 2018

Ferring Collaborates with Chinese Academy of Science on Women's Health

Ferring Pharma, a Swiss company with a focus on reproductive medicine and women’s health, formed a long-term collaboration with the Chinese Academy of Sciences (CAS). As part of the effort, Ferring and CAS established a jointly funded laboratory in a Beijing CAS research facility. It will house Ferring and CAS researchers who will address unmet needs in fertility and high rates of obstetric ...

Suzhou Kintor Raises $44 Million for Novel Drug Portfolio

Suzhou Kintor Pharma raised $44 million in a funding led by Shenzhen Green Pine Capital Partners. Established in 2009, Kintor is an innovative high-tech pharma developing novel products. Since its founding, the company has received over 25 Significant New Drug Creation awards, plus the China Science and Technology Ministry's small and mid-size enterprise innovation funding support along with other...

Hua Medicine to Raise $200 Million to Support Novel Diabetes Drug

Hua Medicine of Shanghai expects to spend $200 million over the next three years on its novel oral diabetes 2 treatment, dorzagliatin. The company will raise additional capital for the effort and then IPO, possibly in Hong Kong or the US. The funds will underwrite Phase III development of its GKA product and commercialization. Ultimately, Hua hopes dorzagliatin will generate annual revenues of $3 ...

WuXi AppTec Forms Clinical Testing JV with the Mayo Clinic

WuXi AppTec formed a JV with the Mayo Clinic to co-develop and deliver novel esoteric clinical diagnostic services in China and the world. Combining WuXi's operational experience with Mayo Medical Lab's clinical and lab expertise, the two groups expect the JV to quickly develop new tests. Each company will offer the tests in their own markets. The clinical testing business is a relatively new offs...

CFDA Plans to Double Drug Review Staff: From 800 to 1,600

According to an article in BioCentury, the CFDA plans to double its drug application reviewers from 800 presently to 1,600 by 2020. In 2015, the CFDA employed just 170 reviewers, meaning the agency will increase its reviewing staff by almost 10-fold over a six-year period. The news was disclosed by Ruyi He, MD, Chief Scientist of the CFDA and the Center for Drug Evaluation, who was speaking at the...

Thursday 11th January 2018

Ping An Signs Strategic Oncology Partnership MOU with Varian

Ping An Health Technology has signed a MOU with Varian, a US maker of radiology machines that treat and manage cancer, to form a strategic partnership for expanding cancer care access in China. The two companies plan to investigate the use of artificial intelligence, cloud computing and big data technologies with the goal of delivering high quality, cost-effective cancer care to more people in Chi...

Shanghai Fosun Forms $50 Million US JV -- With Itself

Shanghai Fosun Pharma announced a $50 million US joint venture, a JV that includes two Fosun entities. Fosun Pharma USA will pay $25.5 million to own a 51% interest in the new JV, which was not named, and Fosun International, the conglomerate that is the parent of Fosun Pharma and its largest shareholder, will contribute the remainder, $24.5 million. Not much is known about the rationale behind th...

Wednesday 10th January 2018

3SBio Approved to Market Once-Weekly Type 2 Diabetes Treatment in China

3SBio reported the CFDA formally approved Bydureon®, its once-weekly Glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes treatment. In 2016, 3SBio in-licensed China rights to Bydureon and a daily GLP-1 product from AstraZeneca in a $100 million agreement (see story). 3SBio. which was not previously involved in the diabetes sector, pointed out that Bydureon is the first once-we...

Aslan Says New CFDA Rules Shave One Year Off Development Time for Lead Drug

Singapore's Aslan Pharma now expects China approval of varlitinib one year earlier than its previous schedule, due to the CFDA's speeding up of approvals for drugs that address an unmet need. Aslan has started a 68-patient China single-arm trial of its lead drug, varlitinib, in patients with advanced or metastatic biliary tract cancer. Following a discussion with the CFDA, Aslan now says it will f...

Fosun Pays $18 Million for China Rights to Novel Parkinson's Disease Drug

Fosun Pharma acquired China rights to market a novel treatment for Parkinson's disease from Portugal's BIAL in an $18 million agreement. BIAL developed Ongentys® (opicapone) as a once-daily adjunctive therapy to levodopa/DOPA decarboxylase inhibitors. It was approved in the EU in 2016. Wanbang Biopharma, a Fosun Pharma subsidiary, will commercialize the drug in China, paying $3 million upfront...

Sinobioway and F1 Oncology to Build Shenzhen CAR-T Manufacturing Facility

Shanghai Sinobioway Sunterra Biotech (SSSB) announced plans to extend its relationship with Florida's F1 Oncology. SSSB will build a production facility, called Shenzhen Biowit, which will offer F1 Oncology's chemically defined suspension-based lentivirus manufacturing technology and processes to China's gene therapy market for CAR-T products and other gene therapies. One year ago, SSSB was formed...


Quick Search
Advertisement

 

News Quicklinks